Quantcast

Latest MEI Pharma Inc. Stories

2014-06-10 08:31:13

Study Meets Pre-Specified CR/CRi Rate in First Nine Patients SAN DIEGO, June 10, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced preliminary response data from the first stage of a two-stage, open-label Phase II clinical study of its investigational drug candidate Pracinostat in combination with Vidaza(®) (azacitidine) in elderly patients with newly diagnosed acute myeloid...

2014-06-09 08:30:15

Live Webcast from Boston on Tuesday, June 17th SAN DIEGO, June 9, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the Wells Fargo Healthcare Conference on Tuesday, June 17, 2014 at 1:45 p.m. Eastern time from the InterContinental in Boston. A live webcast of the presentation can be accessed at...

2014-05-08 08:33:57

Live Webcasts from Las Vegas on May 15th and New York on May 20th SAN DIEGO, May 8, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences: http://photos.prnewswire.com/prnvar/20120628/LA32362LOGO -- The Bank of America Merrill Lynch Health Care Conference on Thursday,...

2014-05-05 08:29:46

SAN DIEGO, May 5, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the first patient has been dosed in a Phase Ib clinical study of its investigational mitochondrial inhibitor drug candidate ME-344 in combination with Hycamtin(®) (topotecan) in patients with solid tumors, including small cell lung and ovarian cancers. The open-label study is expected to enroll up to 64...

2014-04-08 08:31:54

SAN DIEGO, April 8, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today the appointment of David Urso as Senior Vice President of Corporate Development and General Counsel. Mr. Urso joins MEI Pharma with more than two decades of experience in the life science industry, most recently as Chief Operating Officer and General Counsel at Tioga Pharmaceuticals, a company he co-founded in...

2014-04-07 08:31:12

New Pre-Clinical Data Presented at AACR Annual Meeting in San Diego SAN DIEGO, April 7, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced the presentation of new pre-clinical data showing the ability of its lead drug candidate Pracinostat to inhibit bladder cancer cell growth and induce activated transcription factor 3 (ATF-3) expression, a potential marker of tumor response. The data...

2014-04-01 08:30:22

Live Webcast from New York on Tuesday, April 8th SAN DIEGO, April 1, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the Needham Healthcare Conference on Tuesday, April 8, 2014 at 3:00 p.m. Eastern time from the Westin Grand Central Hotel in New York City. A live webcast of the presentation can...

2014-02-28 08:25:51

SAN DIEGO, Feb. 28, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's investigational drug Pracinostat for the treatment of acute myeloid leukemia (AML). (Logo: http://photos.prnewswire.com/prnh/20120628/LA32362LOGO) "We are very pleased to receive this orphan drug...

2014-02-25 08:33:07

Live Webcasts from Boston on March 4th and Laguna Niguel on March 10th SAN DIEGO, Feb. 25, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences: -- The Cowen and Company 34(th) Annual Health Care Conference on Tuesday, March 4, 2014 at 8:40 a.m. Eastern time...

2014-01-14 08:30:33

Data from Three Ongoing Phase II Trials of Pracinostat Anticipated by Year End SAN DIEGO, Jan. 14, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the first patient has been dosed in a Phase II clinical trial of Pracinostat, the Company's investigational oral histone deacetylase (HDAC) inhibitor, in patients with myelodysplastic syndrome (MDS) who either failed to...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related